Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, today has announced that it has successfully completed a large preclinical study in mini-pigs, which shows its OsteoActivator coated collagen membranes to effectively promote new bone formation. The data obtained indicated a 24% increase of new bone within 6 weeks in defects covered by an OsteoActivator membranes as compared to uncoated collagen membranes. Importantly, OsteoActivator membranes were shown to be well tolerated and there were no findings of inflammation.
“We are very encouraged by the results of this clinically relevant mini-pig study that was performed in collaboration with the group of Prof. John Jansen from the Radboud university medical center (Nijmegen, The Netherlands) and are a good basis to advance into clinical studies in 2020” said Jan Gossen, chief executive officer of Osteo-Pharma.
Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable membranes, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in late stage pre-clinical development with various projects and anticipates initiating its first human clinical trials in the course of 2019.